Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 27, 2016
Pharmacy Choice - News - Generic Drugs - May 27, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 38     Next >>     Go To Page:

5/27/16 - Coherus BioSciences Advances Differentiated IP Strategy for Humira Market Access [National News Agency (Lebanon)]
-Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus..
5/27/16 - Generic Injectables
The generic injectable drug segment is a rapidly evolving and highly competitive market that lacks a true data compass to assist decision makers in mapping strategies for success in this segment. Attempting to determine the optimal time to file an ANDA application is a process that can be worth significant profits for first-to-filers.
5/27/16 - Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants [Cihan News Agency (Turkey)]
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Intellipharmaceutics..
5/27/16 - Mylan Launches Generic Frova Tablets
By a News Reporter-Staff News Editor at Drug Week Mylan N.V. announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova Tablets. Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of approximately $88.3 million for the 12 months ending March 31, 2016, according to IMS Health. Currently, Mylan has 26
5/27/16 - Oncobiologics Announces Pricing of Its Initial Public Offering of Units
By a News Reporter-Staff News Editor at Drug Week Oncobiologics, Inc., a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, announced the pricing of its initial public offering of 5,833,334 units at a price to the public of $6.00 per unit.
5/26/16 - Coherus BioSciences Advances Differentiated IP Strategy for Humira Market Access
Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus
5/26/16 - Generic Pharmaceutical Vendor/Wholesaler [TendersInfo (India)]
Tenders are invited for Generic Pharmaceutical Vendor/Wholesaler SCOPE OF CONTRACT: This contract will be used as needed to purchase pharmaceuticals/over-the-counter and medically necessary items from responsive, responsible manufacturers/vendors/wholesalers. Any questions should be submitted in writing to designated contacts by close of...
5/26/16 - Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Intellipharmaceutics.
5/26/16 - JUBILANT LIFE GETS NOD FOR SODIUM CHLORIDE INJECTION
Jubilant HollisterStier LLC, the US subsidiary of Jubilant Life Sciences, has got approval from the US Food and Drug Administration for its abbreviated new drug application for 0.9 percent sodium chloride injection USP, 3 ml and 10 ml vials. The injections are used for diluting or dissolving drugs for IV, IM or subcutaneous injections. The company'
5/26/16 - United States : IFC Invests $30 Mln in Ascendis Health to Promote Access to High-Quality Pharmaceuticals In Emerging Markets [TendersInfo (India)]
IFC, a member of the World Bank Group, will invest up to $30 million in Ascendis Health Limited, a South Africa- based, Johannesburg Stock Exchange listed emerging global leader in life sciences, wellness and nutrition products, to promote access to affordable generic pharmaceuticals and medical products in developing countries. Remedica is a major
5/25/16 - Drug Costs Up in 2013/14 for Canadian Public Drug Plans Due to Increased Spending on High-Cost Drugs; Reduced Savings From Generics
Patented Medicine Prices Review Board. The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, today published the second edition of CompassRx, its flagship annual report that monitors major developments in drug pricing and reimbursement in Canada, analyzes trends, and...
5/25/16 - IFC Invests $30 Mln in Ascendis Health to Promote Access to High-Quality Pharmaceuticals In Emerging Markets
Release date- 24052016- IFC, a member of the World Bank Group, will invest up to $30 million in Ascendis Health Limited, a South Africa- based, Johannesburg Stock Exchange listed emerging global leader in life sciences, wellness and nutrition products, to promote access to affordable generic pharmaceuticals and medical products in developing countr
5/25/16 - Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, joins GPhA Board
Release date- 24052016- London- Hikma Pharmaceuticals PLC,, the fast growing multinational pharmaceutical group, today announces that Michael Raya, Chief Executive Officer of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, will join the Board of Directors of the Generic Pharmaceutical Association. Hikma operates through three.
5/25/16 - Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Release date- 24052016- Holzkirchen- Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche's EU-licensed MabThera. Sandoz is seeking approval for the same indications as the reference product.
5/24/16 - Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
Allergan plc today announced that the New Drug Application filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema associated with rosacea in adults, has been accepted by the U.S. Allergan expects the Prescription Drug User Fee Act date to be in the first half of 201
5/24/16 - Ascendis Health acquires two companies in Europe [Seven Days (United Arab Emirates)]
ASCENDIS Health announced two acquisitions in Europe on Tuesday. The group is buying Cyprus- based pharmaceutical company Remedica for up to 335 m and sports nutrition company Scitec for 170 m. Ascendis expanded into Europe in August by acquiring 49% of Spanish pharmaceutical group Farmalider for R210m with an option to acquire the remaining 51%.
5/24/16 - Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences [Global Data Point]
Prior to joining Avid, Mr. Gagnon spent 25 years as the founder and president of Validated Biosystems, an international consultancy specializing in hands-on development of biological manufacturing processes. Mr. Gagnon is additionally credited with more than 100 scientific journal articles and presentations at major scientific conferences, as well
5/24/16 - Company gets $20 million contract for drug trials at Columbia site [Khaleej Times (United Arab Emirates)]
A $20 million federal contract for testing generic drugs at a Columbia clinic is a vote of confidence for BioPharma Services USA Inc., company officials said Monday. The company on Thursday was awarded the five-year contract with the Center for Drug Evaluation and Research, a division of the U.S. Food and Drug Administration. Todd Pankratz, directo
5/24/16 - Global Active Pharmaceutical Ingredient Market Worth $175 Billion by 2020 - Increased Generic Drug Sales & Regional Penetration - Research and Markets
Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients Global Market- Forecast to 2022" report to their offering. North America dominated the global API market during the forecast period. Moreover the high cost of skilled labor and energy are the major factors that forced European market to shift their base to cou
5/24/16 - Global Active Pharmaceutical Ingredient Market Worth $175 Billion by 2020 - Increased Generic Drug Sales & Regional Penetration - Research and... [Daily News Egypt]
Global Active Pharmaceutical Ingredient Market Worth $175 Billion by 2020- Increased Generic Drug Sales& Regional Penetration- Research and Markets. Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients Global Market- Forecast to 2022" report to their offering. North America dominated the global API market during
5/24/16 - GNW-News: Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency (english)
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency. Novartis International AG/ Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency. Holzkirchen, 24 May, 2016- Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency
5/24/16 - Julphar Bangladesh collaborates to improve availability of high quality medicines in Bangladesh [Emirates News Agency (WAM) (United Arab Emirates)]
RAS AL-KHAIMAH, 24th May, 2016 Julphar Bangladesh, subsidiary of the Ras al-Khaimah- based generic pharmaceutical company Julphar Gulf Pharmaceutical Industries, has announced a strategic agreement with the Bangladeshi non-profit private limited company, SMC Enterprise Limited, SMC-EL, to manufacture pharmaceutical products. Under the terms of th
5/24/16 - Onconova Therapeutics Announces Appointment of Jack E. Stover to Board of Directors [Global Data Point]
Currently, Mr. Stover serves as Interim President, CEO and Director of Interpace Diagnostics Group Inc., a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating the risks of thyroid and pancreatic cancer. In addition to his current position at Interpace Diagnostics Inc., Mr. Stover has served as Pr
5/24/16 - Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors [Kuwait News Agency]
-Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors. Currently, Mr. Stover serves as Interim President, CEO and Director of Interpace Diagnostics Group Inc., a company th
5/24/16 - Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Novartis International AG/ Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency. Processed and transmitted by NASDAQ OMX Corporate Solutions. *Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year* Sandoz is seeking approval for all indications included in the...
Articles(s): 1 - 25 of 38     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415